Phase Ib/II investigator sponsored study of the IDH1-mutant inhibitor ivosidenib (AG120) with the BCL2 inhibitor venetoclax in IDH1-mutated hematologic malignancies. This evidence concerns the gene BCL2 and hematologic disorder.